Antiparkinsonian drugs and dopaminergic neostriatal mechanisms: studies in rats with unilateral 6-hydroxydopamine (=6-OH-DA)-induced degeneration of the nigro-neostriatal DA pathway and quantitative recording of rotational behaviour.
D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001519:Behavior / Q000187:drug effects*; D002395:Catecholamines / Q000378:metabolism; D002421:Caudate Nucleus / Q000502:physiology*; D003342:Corpus Striatum / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D000882:Haplorhini; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology*; D008781:Methyltyrosines / Q000494:pharmacology; D009410:Nerve Degeneration / Q000187:drug effects*; D011699:Putamen / Q000502:physiology*; D051381:Rats; D011955:Receptors, Drug / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects*; D013268:Stimulation, Chemical; D013378:Substantia Nigra / Q000502:physiology*
D000596:Amino Acids; D000978:Antiparkinson Agents; D002395:Catecholamines; D006892:Hydroxydopamines; D008781:Methyltyrosines; D011955:Receptors, Drug; D004298:Dopamine